Pub Date : 1990-01-01DOI: 10.1007/978-3-642-74643-7_48
P A Cassileth, D P Harrington, J D Hines, M M Oken, J J Mazza, P McGlave, J M Bennett, E Lynch, M J O'Connell
{"title":"Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group.","authors":"P A Cassileth, D P Harrington, J D Hines, M M Oken, J J Mazza, P McGlave, J M Bennett, E Lynch, M J O'Connell","doi":"10.1007/978-3-642-74643-7_48","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_48","url":null,"abstract":"","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"267-70"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13334705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1990-01-01DOI: 10.1007/978-3-642-74643-7_52
A Heinecke, M C Sauerland, T Büchner
The ongoing 1985 studies are showing at present no clear advantage for either therapy. In the 1981 study, randomization was terminated by the sequential procedure after 161 randomizations. A test with the same alpha and beta but fixed sample size would have required at least 200 patients, 100 for each therapy. So in this case the use of the sequential procedure saved about 40 randomizations.
{"title":"Sequential decision strategy of the AML Cooperative Group studies.","authors":"A Heinecke, M C Sauerland, T Büchner","doi":"10.1007/978-3-642-74643-7_52","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_52","url":null,"abstract":"<p><p>The ongoing 1985 studies are showing at present no clear advantage for either therapy. In the 1981 study, randomization was terminated by the sequential procedure after 161 randomizations. A test with the same alpha and beta but fixed sample size would have required at least 200 patients, 100 for each therapy. So in this case the use of the sequential procedure saved about 40 randomizations.</p>","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"290-4"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13334708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1990-01-01DOI: 10.1007/978-3-642-74643-7_61
J M Rowe, J J Mazza, J D Hines, P A Cassileth, M M Oken, J M Bennett, J Andersen
{"title":"Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia.","authors":"J M Rowe, J J Mazza, J D Hines, P A Cassileth, M M Oken, J M Bennett, J Andersen","doi":"10.1007/978-3-642-74643-7_61","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_61","url":null,"abstract":"","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"326-9"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13334712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1990-01-01DOI: 10.1007/978-3-642-74643-7_75
B Clarkson, J Gaynor, C Little, E Berman, S Kempin, M Andreeff, S Gulati, I Cunningham, T Gee
During the past 20 years, we have treated 250 previously untreated adults (greater than age 15 years) with acute lymphoblastic leukemia (ALL) with five successive multidrug protocols: L2, L10, L10M, L17/17M, and L20. The L10 and L10M protocols had the highest percentage of long-term (greater than 5 years) remissions (52% and 40% respectively) compared with the L2 and more recent protocols (24%-32%); this is partly attributable to a greater prevalence of adverse risk factors among the latter protocols. The overall long-term survival of the first 199 patients with minimum 3 years follow-up is now 31%, with 35% of the 163 patients achieving complete remission (CR) remaining free of relapse for greater than 5 years. The disease-free survival of the 163 patients reaches a plateau of 33% after 6 years. The percentages of patients subsequently relapsing after remaining in continuous CR for 1.5, 3, and 5 years are 42%, 28%, and 6%, respectively; no relapses have yet occurred after 6 years in this series. Postrelapse survival improved progressively with longer duration of first remission. The results of treatment in second or later remission with either chemotherapy or bone marrow transplantation (BMT) were unsatisfactory and there were only a few long-term survivors. Recently we have attempted to select patients at highest risk of early relapse for BMT in first remission, but the number of eligible patients actually having BMTs has been low for a variety of reasons, including early death, failure to reach CR, early relapse, patient refusal, or medical contraindications.(ABSTRACT TRUNCATED AT 250 WORDS)
{"title":"Importance of long-term follow-up in evaluating treatment regimens for adults with acute lymphoblastic leukemia.","authors":"B Clarkson, J Gaynor, C Little, E Berman, S Kempin, M Andreeff, S Gulati, I Cunningham, T Gee","doi":"10.1007/978-3-642-74643-7_75","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_75","url":null,"abstract":"<p><p>During the past 20 years, we have treated 250 previously untreated adults (greater than age 15 years) with acute lymphoblastic leukemia (ALL) with five successive multidrug protocols: L2, L10, L10M, L17/17M, and L20. The L10 and L10M protocols had the highest percentage of long-term (greater than 5 years) remissions (52% and 40% respectively) compared with the L2 and more recent protocols (24%-32%); this is partly attributable to a greater prevalence of adverse risk factors among the latter protocols. The overall long-term survival of the first 199 patients with minimum 3 years follow-up is now 31%, with 35% of the 163 patients achieving complete remission (CR) remaining free of relapse for greater than 5 years. The disease-free survival of the 163 patients reaches a plateau of 33% after 6 years. The percentages of patients subsequently relapsing after remaining in continuous CR for 1.5, 3, and 5 years are 42%, 28%, and 6%, respectively; no relapses have yet occurred after 6 years in this series. Postrelapse survival improved progressively with longer duration of first remission. The results of treatment in second or later remission with either chemotherapy or bone marrow transplantation (BMT) were unsatisfactory and there were only a few long-term survivors. Recently we have attempted to select patients at highest risk of early relapse for BMT in first remission, but the number of eligible patients actually having BMTs has been low for a variety of reasons, including early death, failure to reach CR, early relapse, patient refusal, or medical contraindications.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"397-408"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13334715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1990-01-01DOI: 10.1007/978-3-642-74643-7_114
R Storb, C D Buckner, R A Clift, F R Appelbaum, K C Doney, P Martin, C Anasetti, J Hansen, J E Sanders, F B Petersen
{"title":"Marrow grafting for acute leukemia: results and future treatment strategies.","authors":"R Storb, C D Buckner, R A Clift, F R Appelbaum, K C Doney, P Martin, C Anasetti, J Hansen, J E Sanders, F B Petersen","doi":"10.1007/978-3-642-74643-7_114","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_114","url":null,"abstract":"","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"629-35"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13335244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1990-01-01DOI: 10.1007/978-3-642-74643-7_116
D Niethammer, T Klingebiel, R Dopfer, G Ehninger, G Henze, W Schaefer, B Stollmann, W Ebell, M Link, H Riehm
{"title":"Allogeneic bone marrow transplantation in childhood leukemia: results and strategies in the Federal Republic of Germany.","authors":"D Niethammer, T Klingebiel, R Dopfer, G Ehninger, G Henze, W Schaefer, B Stollmann, W Ebell, M Link, H Riehm","doi":"10.1007/978-3-642-74643-7_116","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_116","url":null,"abstract":"","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"638-48"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13335245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1990-01-01DOI: 10.1007/978-3-642-74643-7_85
A J Veerman, K Hählen, W A Kamps, E F Vanleeuwen, G A de Vaan, E R Vanwering, A Vanderdoes-Vandenberg, G Solbu, S Suciu
{"title":"Dutch Childhood Leukemia Study Group: early results of study ALL VI (1984-1988).","authors":"A J Veerman, K Hählen, W A Kamps, E F Vanleeuwen, G A de Vaan, E R Vanwering, A Vanderdoes-Vandenberg, G Solbu, S Suciu","doi":"10.1007/978-3-642-74643-7_85","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_85","url":null,"abstract":"","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"473-7"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13335934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1990-01-01DOI: 10.1007/978-3-642-74643-7_88
G E Janka-Schaub, U Goebel, U Graubner, R J Haas, H Juergens, H J Spaar, K Winkler
{"title":"Improved prognosis for childhood acute lymphocytic leukemia with very high white blood cell count (greater than 100/nl) with rotation of non-cross-resistant drug combinations.","authors":"G E Janka-Schaub, U Goebel, U Graubner, R J Haas, H Juergens, H J Spaar, K Winkler","doi":"10.1007/978-3-642-74643-7_88","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_88","url":null,"abstract":"","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"489-93"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13335937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1990-01-01DOI: 10.1007/978-3-642-74643-7_99
M von Eiff, M Essink, N Roos, H Schmidt, W Hiddemann, T Büchner, J van de Loo
{"title":"Hepatosplenic candidiasis in acute leukemias.","authors":"M von Eiff, M Essink, N Roos, H Schmidt, W Hiddemann, T Büchner, J van de Loo","doi":"10.1007/978-3-642-74643-7_99","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_99","url":null,"abstract":"","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"555-7"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13473553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：